SMX (Security Matters) Public Limited Company is an Irish-domiciled Nasdaq issuer whose molecular-marker technology still has not produced recurring commercial sales, even after a first-half cash raise that rebuilt the balance sheet. The investment debate is not whether the marker-and-reader stack can authenticate plastics or metals in a laboratory setting. It is whether a pre-revenue circular-economy story can convert pilots in Singapore, the Emirates, and Japan into billed contracts before the standby equity line and a long string of reverse share consolidations consume the residual claim. Auditor Ziv Haft already attached substantial-doubt language to the last audited accounts. The mid-year print does not reverse that verdict. It refinances it.
Cash at mid-year sat near $34 million after about $51 million of net proceeds from the Target Capital standby facility. Operating cash use in the same half ran about $25 million, several times the year-ago burn, because professional-services spending and commercialization overhead expanded faster than any offsetting receipt. The company still reports no recurring technology revenue. That combination is the real print: liquidity improved only because ordinary shares were issued into a thin tape, not because the product started to pay for itself.
Net loss widened to $45 million. Accumulated losses now exceed $296 million. Eight reverse consolidations since January of last year kept the Nasdaq bid-price test alive while shrinking the share count that the market still capitalizes at roughly $19 million. The question the next two interims resolve is simple. Does a named, recurring commercial contract appear on the income statement, or does the equity line remain the only functioning product?